A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2

The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Here, the authors show that VEGFRs peptide vaccination can improve hearing and reduce tumor volume in NF2 patients, including in previously bevacizumab resi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ryota Tamura, Masato Fujioka, Yukina Morimoto, Kentaro Ohara, Kenzo Kosugi, Yumiko Oishi, Mizuto Sato, Ryo Ueda, Hirokazu Fujiwara, Tetsuro Hikichi, Shinobu Noji, Naoki Oishi, Kaoru Ogawa, Yutaka Kawakami, Takayuki Ohira, Kazunari Yoshida, Masahiro Toda
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/ea9146bdc0434722af7229b82fabc004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ea9146bdc0434722af7229b82fabc004
record_format	dspace
spelling	oai:doaj.org-article:ea9146bdc0434722af7229b82fabc0042021-12-02T15:35:49ZA VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 210.1038/s41467-019-13640-12041-1723https://doaj.org/article/ea9146bdc0434722af7229b82fabc0042019-12-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-13640-1https://doaj.org/toc/2041-1723The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Here, the authors show that VEGFRs peptide vaccination can improve hearing and reduce tumor volume in NF2 patients, including in previously bevacizumab resistant tumors.Ryota TamuraMasato FujiokaYukina MorimotoKentaro OharaKenzo KosugiYumiko OishiMizuto SatoRyo UedaHirokazu FujiwaraTetsuro HikichiShinobu NojiNaoki OishiKaoru OgawaYutaka KawakamiTakayuki OhiraKazunari YoshidaMasahiro TodaNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Ryota Tamura Masato Fujioka Yukina Morimoto Kentaro Ohara Kenzo Kosugi Yumiko Oishi Mizuto Sato Ryo Ueda Hirokazu Fujiwara Tetsuro Hikichi Shinobu Noji Naoki Oishi Kaoru Ogawa Yutaka Kawakami Takayuki Ohira Kazunari Yoshida Masahiro Toda A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
description	The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Here, the authors show that VEGFRs peptide vaccination can improve hearing and reduce tumor volume in NF2 patients, including in previously bevacizumab resistant tumors.
format	article
author	Ryota Tamura Masato Fujioka Yukina Morimoto Kentaro Ohara Kenzo Kosugi Yumiko Oishi Mizuto Sato Ryo Ueda Hirokazu Fujiwara Tetsuro Hikichi Shinobu Noji Naoki Oishi Kaoru Ogawa Yutaka Kawakami Takayuki Ohira Kazunari Yoshida Masahiro Toda
author_facet	Ryota Tamura Masato Fujioka Yukina Morimoto Kentaro Ohara Kenzo Kosugi Yumiko Oishi Mizuto Sato Ryo Ueda Hirokazu Fujiwara Tetsuro Hikichi Shinobu Noji Naoki Oishi Kaoru Ogawa Yutaka Kawakami Takayuki Ohira Kazunari Yoshida Masahiro Toda
author_sort	Ryota Tamura
title	A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
title_short	A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
title_full	A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
title_fullStr	A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
title_full_unstemmed	A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
title_sort	vegf receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/ea9146bdc0434722af7229b82fabc004
work_keys_str_mv	AT ryotatamura avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT masatofujioka avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yukinamorimoto avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kentaroohara avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kenzokosugi avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yumikooishi avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT mizutosato avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT ryoueda avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT hirokazufujiwara avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT tetsurohikichi avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT shinobunoji avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT naokioishi avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kaoruogawa avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yutakakawakami avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT takayukiohira avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kazunariyoshida avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT masahirotoda avegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT ryotatamura vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT masatofujioka vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yukinamorimoto vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kentaroohara vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kenzokosugi vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yumikooishi vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT mizutosato vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT ryoueda vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT hirokazufujiwara vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT tetsurohikichi vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT shinobunoji vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT naokioishi vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kaoruogawa vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT yutakakawakami vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT takayukiohira vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT kazunariyoshida vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2 AT masahirotoda vegfreceptorvaccinedemonstratespreliminaryefficacyinneurofibromatosistype2
_version_	1718386448710762496

A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2

Ejemplares similares